We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

This study is currently recruiting participants.
Verified May 2017 by Eli Lilly and Company
Sponsor:
ClinicalTrials.gov Identifier:
NCT02564198
First Posted: September 30, 2015
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Children's Oncology Group
Information provided by (Responsible Party):
Eli Lilly and Company
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2019
  Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)